Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Merger or Acquisition (August 2015)

14 slides from Sucampo Pharmaceuticals's merger presentation, Aug 26, 2015

  1. Slide 1: Tender Offer to Acquire R-Tech Ueno

    Tender Offer to Acquire R-Tech Ueno August 26, 2015 $ sucampo The Science of Innovation

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements presentation, e $ sucamPo 2 The Science of Innovation

  3. Slide 3: Important Information for Investors and Shareholders

    Important Information for Investors and Shareholders The offer Japan. i ion i i Ff an offer to purchase nor p y securities. e $ sucamPo 3 The Science of Innovation

  4. Slide 4: Acquisition of R-Tech Ueno

    Acquisition of R-Tech Ueno offer | e @ SUCAMPO The Science of Innovation

  5. Slide 5: Strategic Benefits

    Strategic Benefits y Increased revenues Enhanced profitability Stronger cash flow generation e 2 SUCAMPO 5 he Science of Innovation

  6. Slide 6: 2016 Guidance and Synergies

    2016 Guidance and Synergies For FY 2016, i izati ion, expect: e Net income of $55 - $60M e EPS of $1.20 - $1.30 e Adjusted EBITDA of $95M - $100M. e @ SUCAMPO 6 The Science of Innovation

  7. Slide 7: Transaction Highlights

    Transaction Highlights ° ¢ 16% premium over * 16% premium over Tender offer 567 f R-Tech U ° 1,900 Japanese yen per share shares ° 1,400 Japanese yen per share e ? SUCAMPO The Science of Innovation

  8. Slide 8: Transaction Timing and Financing

    Transaction Timing and Financing Tender offer e Concludes October 13, 2015 e @ SUCAMPO 8 The Science of Innovation

  9. Slide 9: R-Tech Ueno Overview

    R-Tech Ueno Overview of AMITIZA p' Takeda e Gastroenterology e Ophthalmology ° e Oncology AMITIZA revenue e Increased 33% YoY Ain Japan ° ~ 25% of FY 2014 sales e ? SUCAMPO The Science of Innovation

  10. Slide 10: Key Drivers

    Key Drivers 1. 4 on AMITIZA ° Takeda partners ¢ 10 oY SUCAMPO he Science of Innovation

  11. Slide 11: Target First Indication Development Comments

    = — Z Z Target First Indication Develepaient ‘Comments Stage Gl/Metabolic/inflammation EEE Microparticle icp Pediatric functional constipation; adi P3. New liquid-like formulation cu BK2 Retinitis —— PS Financial —— ‘in Japan by AMED- cae SS ae rm Sicampo Program))|_ R-Tech Ueno Program $ SUCAMPO ii

  12. Slide 12: VAP-1 Inhibitor Programs

    VAP-1 Inhibitor Programs RTU-1069 (Oral) e NASH, COPD, di i i immune-oncology e Phase 1 SAD completed e Phase 1 MAD is next step RTU-009 (IV) e IND-enabling studies are next step ¢ 12 @ SUCAMPO The Science of Innovation

  13. Slide 13: Conclusion

    Conclusion opportunities development-stage products $ suCAMPO 3 @ “The Sclence of Innovation

  14. Slide 14: e ?

    e ? SUCAMPO The Science of Innovation

Sucampo Pharmaceuticals — Merger or Acquisition (August 2015) on 6ix